These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34143346)

  • 1. The economic burden of amyotrophic lateral sclerosis: a systematic review.
    Achtert K; Kerkemeyer L
    Eur J Health Econ; 2021 Nov; 22(8):1151-1166. PubMed ID: 34143346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic impact of amyotrophic lateral sclerosis: a systematic review.
    Gladman M; Zinman L
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):439-50. PubMed ID: 25924979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.
    Oh J; Kim JA
    J Clin Nurs; 2017 Dec; 26(23-24):4129-4152. PubMed ID: 28681543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany.
    Schönfelder E; Osmanovic A; Müschen LH; Petri S; Schreiber-Katz O
    Orphanet J Rare Dis; 2020 Jun; 15(1):149. PubMed ID: 32532288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' self-perceived burden, caregivers' burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study.
    Geng D; Ou R; Miao X; Zhao L; Wei Q; Chen X; Liang Y; Shang H; Yang R
    J Clin Nurs; 2017 Oct; 26(19-20):3188-3199. PubMed ID: 27874996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review.
    Berry JD; Blanchard M; Bonar K; Drane E; Murton M; Ploug U; Ricchetti-Masterson K; Savic N; Worthington E; Heiman-Patterson T
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Aug; 24(5-6):436-448. PubMed ID: 36748473
    [No Abstract]   [Full Text] [Related]  

  • 7. WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003457. PubMed ID: 18425887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2003; (4):CD003457. PubMed ID: 14583978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Mustfa N
    Cochrane Database Syst Rev; 2013 Mar; (3):CD004427. PubMed ID: 23543531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses.
    Gladman M; Dharamshi C; Zinman L
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):426-32. PubMed ID: 25025935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences of burden, needs, rewards and resilience in family caregivers of people living with Motor Neurone Disease/Amyotrophic Lateral Sclerosis: A secondary thematic analysis of qualitative interviews.
    Weisser FB; Bristowe K; Jackson D
    Palliat Med; 2015 Sep; 29(8):737-45. PubMed ID: 25762578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial cost of amyotrophic lateral sclerosis: a case study.
    Obermann M; Lyon M
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):54-7. PubMed ID: 25245119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Brassington R; Mustfa N
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD004427. PubMed ID: 28982219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease.
    Orrell RW; Lane RJ; Ross M
    Amyotroph Lateral Scler; 2008 Aug; 9(4):195-211. PubMed ID: 18608090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for fatigue and weight loss in adults with advanced progressive illness.
    Payne C; Wiffen PJ; Martin S
    Cochrane Database Syst Rev; 2012 Jan; 1():CD008427. PubMed ID: 22258985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease.
    Bongioanni P; Reali C; Sogos V
    Cochrane Database Syst Rev; 2004; 2004(3):CD004302. PubMed ID: 15266526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system.
    Oh J; An JW; Oh SI; Oh KW; Kim JA; Lee JS; Kim SH
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Jun; 16(3-4):202-8. PubMed ID: 25646865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.